Previously [30], we used our proposed molecular mechanisms of transmembrane signaling [46,47] and targeted drug and imaging agent delivery [52,53] to design TREM-1 inhibitory peptide sequence GF9, and demonstrated that prophylactic administration of GF9 as a free peptide GF9 or delivered in the HDL-mimicking macrophage-targeted LPC formulations, efficiently reduces arthritis progression and protects against bone and cartilage damage in mice with CIA, the most widely studied autoimmune model of RA [54]. Here, TREM1 is linked to arthritic joint disease.